



BEHQ-97-14001

## CHEMICAL MANUFACTURERS' ASSOCIATION

Via Certified Mail

August 15, 1997

8EHQ - 0897 - 14001  
D

Document Processing Center  
Office of Pollution Prevention and Toxics  
Section 8(e) Coordinator  
U.S. Environmental Protection Agency  
401 M Street, SW  
Washington DC 20460-0001

Contains NO CBI

97 AUG 19 AM 11:27

RECEIVED  
OPPT/CPC

CAS NO. 74-83-9

Re: TSCA Section 8(e) Reporting Notification for Methyl Bromide

Dear Sir or Madam:

On behalf of the Methyl Bromide Industry Panel (MBIP) and its members, the Chemical Manufacturers Association submits for your office's information, notice of a report regarding methyl bromide that has been submitted to EPA which may be subject to Section 6(a)(2) of the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) and the EPA guidance on Section 6(a)(2) reporting requirements published in the Federal Register on July 12, 1979 (1979 Guidance). The MBIP consists of three manufacturers of the technical product - Albemarle Corporation (formerly part of Ethyl Corporation), Ameribrom, Inc. and Great Lakes Chemical Corporation - and one major formulator, TriCal, Inc.

The MBIP contracted a consultant pathologist - Dr. Jerry F. Hardisty, D.V.M., Diplomate, A.C.V.P, Experimental Pathology Laboratories, Inc., PO Box 12766, Research Triangle Park, NC 27709 - to reexamine all sections prepared from the nasal cavities from all animal in a 29-month Chronic Inhalation Toxicity and Carcinogenicity Study of Methyl Bromide in Rats conducted at the Netherlands Organization for Applied Scientific Research (TNO), Division for Nutrition and Food Research, Zeist, Netherlands (MRID No. 41213301). The Reexamination Report is enclosed.

The results of this reexamination confirmed the majority of the findings reported initially by the original study pathologist. However, there were several differences noted. These differences resulted in a no-observed-effect level (NOEL) of 3 ppm.


In light of a consistent policy on the applicability of TSCA to chemicals also regulated under FIFRA, the MBIP is notifying the TSCA 8(e) Coordinator of the enclosed submission to the Office of Pesticide Programs as a precaution.

If you have questions concerning this report, please call me at (703) 741-5635.

Sincerely,

*Susan A. Lewis*Susan A. Lewis, Ph.D.  
Manager, MBIP

88970000251



Enclosure

cc: MBIP Members



INNOVATION, TECHNOLOGY AND RESPONSIBLE CARE® AT WORK

1300 WILSON BLVD., ARLINGTON, VA 22209 • TELEPHONE 703-741-5000 • FAX 703-741-6000

97 AUG 25 PM 8:10

RECEIVED  
OPPT/MC/C

**EPL®**

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

**CHRONIC (29-MONTH) INHALATION TOXICITY  
AND CARCINOGENICITY STUDY OF  
METHYL BROMIDE IN RATS**

**REEXAMINATION OF NASAL CAVITY**

**STUDY NO. B-91-8213/002**

**RECEIVED  
OPPT CBIC**

**97 AUG 19 AM 11:27**

**Submitted to:**

**The Methyl Bromide Industry Panel  
Chemical Manufacturer's Association  
1300 Wilson Blvd.  
Arlington, VA 22209**

**RECEIVED  
OPPT NCIC**

**97 AUG 25 AM 8:10**

**Submitted by:**

**Experimental Pathology Laboratories, Inc.  
P.O. Box 12766  
Research Triangle Park, NC 27709  
(919)544-8061**

**July 21, 1997**

**TABLE OF CONTENTS**

	<b>Page</b>
Narrative Summary . . . . .	1
APPENDIX A - 52-WEEK INTERIM	
Slide Review Work Sheets - Males . . . . .	A-1 - A-4
APPENDIX B - 52-WEEK INTERIM	
Slide Review Work Sheets - Females . . . . .	B-1 - B-4
APPENDIX C - 104-WEEK INTERIM	
Slide Review Work Sheets - Males . . . . .	C-1 - C-4
APPENDIX D - 104-WEEK INTERIM	
Slide Review Work Sheets - Females . . . . .	D-1 - D-4
APPENDIX E - TERMINAL	
Slide Review Work Sheets - Males . . . . .	E-1 - E-15
APPENDIX F - TERMINAL	
Slide Review Work Sheets - Females . . . . .	F-1 - F-18

Study Number B-91-8213/002

**CHRONIC (29-MONTH) INHALATION  
TOXICITY AND CARCINOGENICITY STUDY OF METHYL BROMIDE  
IN RATS: REEXAMINATION OF THE NASAL CAVITY**

STUDY NUMBER B-91-8213/002

**NARRATIVE SUMMARY**

**INTRODUCTION**

A toxicity and carcinogenicity study of methyl bromide (MeBr) in male and female Wistar rats, exposed by inhalation to 0, 3, 30 or 90 ppm MeBr 6 hr/day, 5 days/wk for 29 months was conducted at the Netherlands Organization for Applied Scientific Research (TNO), Division for Nutrition and Food Research, Zeist, Netherlands. After 52 and 104 weeks 10 rats/sex/group were killed for interim information. The results of this study were reported by the The Methyl Bromide Industry on March 7, 1985 (Laboratory Project ID: CIVO/TNO; Report No. V 86.469/221044). A supplement to the original report was submitted by The Methyl Bromide Industry Panel in February 1992 (Laboratory Project ID B-91-8213/002) to include individual animal data which was not included in the original submission. The findings from this Chronic Inhalation Toxicity and Carcinogenicity Study of Methyl Bromide in Wistar Rats were published by Reuzel, et al., 1991. A summary of the experimental design for the study is presented on the following page:

Study Number B-91-8213/002

Table I: Experimental Design of a Chronic Inhalation Toxicity and Carcinogenicity Study of Methyl Bromide in Wistar Rats

Sacrifice Interval		Number of Animals					
		52 Weeks		104 Weeks		Terminal	
Group	Exposure Level (ppm)	M	F	M	F	M	F
A	0	10	10	10	10	50	60
B	3	10	10	10	10	50	60
C	30	10	10	10	10	50	60
D	90	10	10	10	10	50	60

#### MATERIALS AND METHODS

At the request of the Chemical Manufacturer's Association's Methyl Bromide Panel, Dr. Jerry F. Hardisty, Experimental Pathology Laboratories, Inc. (EPL®), reexamined all sections prepared from the nasal cavity from all animals in all groups to review the accuracy and consistency of the initial diagnoses reported by the study pathologist. This included reexamination of cross sections of the nose taken at four levels from control and high dose (90 ppm) animals sacrificed at 52 weeks and six (6) levels from control and high exposure (90 ppm) animals included in the 104 week scheduled sacrifice and from the main portion of the study (terminal sacrifice). For animals in the low (3 ppm) and mid (30 ppm) exposure levels, sections were generally prepared for

Study Number B-91-8213/002

examination only from Levels II and III which had been identified as the site of changes associated with Methyl Bromide exposure. Although all changes diagnosed initially by the study pathologist were reexamined, the review concentrated primarily on changes in the nasal cavity that were considered to be associated with exposure to methyl bromide by the study pathologist. These changes were restricted to the dorso-medial part of the nasal cavity (Levels II and III) and consisted of basal cell hyperplasia, occasionally accompanied by cystic structures. The overlying epithelium showed degeneration, seen as thinning of the layer.

The reexamination of the slides was performed at the Netherlands Organization for Applied Scientific Research (TNO), Zeist, Netherlands on July 2-4, 1997. Following the reexamination of the nasal sections, differences noted between the results of the review and the original findings initially reported were discussed between the reviewing pathologist, Dr. Jerry F. Hardisty, and the study pathologist, Dr. C.F. Kuper, with agreement on the final diagnosis for each difference. The initial diagnoses and the results of the reexamination are tabulated for each animal in the Slide Review Worksheets included in Appendices A-F.

The Slide Review Work Sheets list for each animal the number of slides examined and the specific tissues examined. The column designated "Study Pathologist" lists all diagnoses in the nasal cavity

Study Number B-91-8213/002

initially reported by the study pathologist. The column designated "Reviewing Pathologist" indicates agreement with the initial finding or lists differences in diagnoses resulting from the reexamination of the slides. For each difference noted by the reviewing pathologist, the slide number of the tissue corresponding with the difference is noted in the column for "Reviewing Pathologist" on the Slide Review Work Sheets.

**RESULTS**

The results of this reexamination confirmed the majority of the findings reported initially by the study pathologist. Degenerative and hyperplastic changes involving the olfactory epithelium lining the dorsal meatus of Levels II and III of the nasal cavity were present in all exposure groups including controls. There were several differences noted during the review, however, that involved the incidence of changes attributed to methyl bromide exposure. These generally involved lesions that were considered to be very slight during the initial examination of the nasal sections but were considered to be normal during the reexamination. Exposure-related changes were also noted in a few animals during the reexamination that were not initially reported. These differences were noted in all exposure groups, but they effected the interpretation of exposure-related changes in the low dose group (3 ppm). In the final study report, an increased incidence of slight

Study Number B-91-8213/002

degeneration and hyperplastic changes (basal cell hyperplasia) of the olfactory epithelium in the dorso-medial part of the nasal cavity were reported in males and females of each of the test groups. In the 3 ppm group, the changes were only minimal. The hyperplastic changes showed statistically significant (Fisher's exact probability test) concentration-related increases in male and female rats in all exposure groups (Reuzel, et al., 1991). Following the reexamination, there were no statistically significant (Fisher's exact probability test) differences in the incidence of basal cell hyperplasia in the control (0 ppm) and low exposure (3 ppm) groups. Exposure related differences were present in the incidence of basal cell hyperplasia in male and female rats in the mid (30 ppm) and high (90 ppm) exposure groups as compared to the control groups (Tables II-IV). The low exposure (3 ppm) group is considered to represent a no-observed-effect-level (NOEL) for inhalation exposure to methyl bromide in rats for up to 29 months.

At the 52 week sacrifice, exposure-related increases in basal cell hyperplasia were present only in the high exposure (90 ppm) group of male rats. After 104 weeks of exposure and in the main study group (terminal sacrifice) exposed for up to 29 months, the incidence and severity of basal cell hyperplasia were increased in male and female rats in the mid (30 ppm) and high (90 ppm) exposure groups as compared to male and female rats in the control (0 ppm) and low (3 ppm)

**EPL®**

---

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

---

Study Number B-91-8213/002

dose exposure groups. The severity of basal cell hyperplasia increased only slightly over the course of the study in the effected groups. A summary of the initial findings reported by the study pathologist and the results of the reexamination of the slides are presented in Table II (52 Week Sacrifice), Table III (104 Week Sacrifice), and Table IV (Terminal Sacrifice).

Study Number B-91-8213/002

**Table II: Summary Comparing the Incidence and Severity of Basal Cell Hyperplasia Reported Initially and Following Reexamination of the Nasal Cavity for Male and Female Rats at the 52 Week Interim Sacrifice**

	Diagnoses Included in the Final Study Report					Diagnoses Resulting from the Reexamination			
	0	3	30	90		0	3	30	90
<b>52 Week Interim Sacrifice (Male Rats)</b>									
Exposure Group (ppm)	0	3	30	90		0	3	30	90
Nasal Cavity (No. Examined)	(10)	(10)	(10)	(10)		(10)	(10)	(10)	(10)
Basal Cell Hyperplasia (Total)	3	0	1	5		1	1	1	6*
Very Slight	3		1			1		1	1
Slight				2			1		3
Moderate				3					2
<b>52 Week Interim Sacrifice (Female Rats)</b>									
Exposure Group (ppm)	0	3	30	90		0	3	30	90
Nasal Cavity (No. Examined)	(10)	(8)	(10)	(10)		(10)	(8)	(10)	(10)
Basal Cell Hyperplasia (Total)	0	0	1	2		0	0	1	2
Very Slight			1					1	
Slight				2					2
Moderate									

Values marked with asterisks differ significantly (Fisher's exact probability test) from the corresponding control values (\* P<0.05; \*\* P<0.01).

Study Number B-91-8213/002

**Table III:** Summary Comparing the Incidence and Severity of Basal Cell Hyperplasia Reported Initially and Following Reexamination of the Nasal Cavity for Male and Female Rats at the 104 Week Interim Sacrifice

	Diagnoses Included in the Final Study Report					Diagnoses Resulting from the Reexamination			
104 Week Interim Sacrifice (Male Rats)									
Exposure Group (ppm)	0	3	30	90		0	3	30	90
Nasal Cavity (No. Examined)	(10)	(8)	(10)	(10)		(10)	(10)	(10)	(10)
Basal Cell Hyperplasia (Total)	3	0	4	6		1	0	5	6*
Very Slight	1		3			1		4	
Slight	2		1	4				1	5
Moderate				2					1
104 Week Interim Sacrifice (Female Rats)									
Exposure Group (ppm)	0	3	30	90		0	3	30	90
Nasal Cavity (No. Examined)	(9)	(10)	(10)	(9)		(9)	(10)	(10)	(9)
Basal Cell Hyperplasia (Total)	4	2	5	7		3	2	5	7
Very Slight	1	1		2		2	1	1	2
Slight	2	1	4	2		1	1	3	2
Moderate	1		1	3				1	3

Values marked with asterisks differ significantly (Fisher's exact probability test) from the corresponding control values (\* P<0.05; \*\* P<0.01).

Study Number B-91-8213/002

**Table IV:** Summary Comparing the Incidence and Severity of Basal Cell Hyperplasia Reported Initially and Following Reexamination of the Nasal Cavity for Male and Female Rats Exposed for up to 29 Months (Terminal Sacrifice)

	Diagnoses Included in the Final Study Report					Diagnoses Resulting from the Reexamination			
	0	3	30	90		0	3	30	90
TERMINAL SACRIFICE (MALE RATS)									
Exposure Group (ppm)	0	3	30	90		0	3	30	90
Nasal Cavity (No. Examined)	(46)	(48)	(49)	(48)		(46)	(48)	(49)	(48)
Basal Cell Hyperplasia (Total)	4	13*	23**	31**		4	9	20**	33**
Very Slight	2	9	7	8		3	6	5	10
Slight	2	3	12	14		1	2	11	14
Moderate		1	4	9			1	4	9
TERMINAL SACRIFICE (FEMALE RATS)									
Exposure Group (ppm)	0	3	30	90		0	3	30	90
Nasal Cavity (No. Examined)	(59)	(60)	(59)	(59)		(59)	(60)	(59)	(59)
Basal Cell Hyperplasia (Total)	7	19**	25*	42**		6	11	22**	39**
Very Slight	6	17	13	10		6	9	12	13
Slight	1	2	9	23			2	7	18
Moderate			3	9				3	8

Values marked with asterisks differ significantly (Fisher's exact probability test) from the corresponding control values (\* P<0.05; \*\* P<0.01).

Study Number B-91-8213/002

During the reexamination of the sections of nasal cavity there were several observations made concerning tissues which were missing or discrepancies resulting from errors that occurred during the histologic preparation of the tissues for microscopic examination. Tissue sections which were missing were either discarded due to autolysis or were lost during histologic processing.

Examination of the tissue sections for three animals, indicated that the slides were mislabeled during slide preparation. Three slides were present for animal C051. Two of the slides were labeled as Level III. One of these slides was severely autolyzed while the second had no autolysis. The third slide was labeled as Level II and also was not autolyzed. This indicated that the autolyzed slide labeled Level III was from a different animal. Animal C0151 had only one slide present. This slide was labeled as Level II and a slide for Level III was missing. The tissue on the slide labeled Level II was severely autolyzed similar to the autolyzed slide from animal C051. A check of the blocks for these two animals, indicated three blocks for animal C051 and one block for animal C0151. Since the labeling of the blocks matched the labeling of the slides, it was not possible to resolve the discrepancy.

Twelve (12) slides were present for animal A023. Six of the slides had rhinitis and six of the slides had no evidence of rhinitis,

Study Number B-91-8213/002

indicating that the slides were from two different animals. A check of the blocks revealed that there were 12 blocks labeled for animal A023, therefore the discrepancy could not be resolved.

Slides were present for two male rats from the 104 week interim sacrifice (B120 and B128) that were initially reported as having no section by the study pathologist. No remarkable lesions were present in the sections from animal B120. In the sections from animal B128, no abnormalities were present in the nasal cavity but an odontogenic fibrosarcoma arising from the tooth was present.

Other differences noted during the reexamination of the slides were varied and did not effect the overall interpretation of the results from the study. These differences generally involved the presence of inflammatory changes which had not been reported initially, differences in terminology, or differences in severity grades for lesions which were confirmed as present.

### CONCLUSIONS

The results of a reexamination of the nasal sections from male and female Wistar rats exposed via inhalation to methyl bromide for up to 29 months confirmed the original findings of a statistically significant increased incidence of basal cell hyperplasia involving the olfactory epithelium lining the anterior dorsal meatus of the nasal

Study Number B-91-8213/002

cavity in the mid (30 ppm) and high (90 ppm) exposure groups of both sexes as compared to control male and female rats. The reexamination, however, indicated that there was no statistically significant (Fisher's exact probability test) difference in the incidence of basal cell hyperplasia in male or female rats in the control (0 ppm) and low (3 ppm) exposure groups. The low exposure (3 ppm) group is considered to represent a no-observed-effect-level (NOEL) for lesions involving the nasal cavity following inhalation exposure to methyl bromide in rats for up to 29 months.

*Jerry F. Hardisty, D.V.M.*  
JERRY F. HARDISTY, D.V.M.

Diplomate, A.C.V.P.  
Reviewing Pathologist

*July 21, 1997*  
July 21, 1997  
Date

Study Number B-91-8213/002

**REFERENCES**

- Reuzel, P.G.J., Dreef-van der Meulen, H.C., Hollanders, V.M.H., Kuper, C.F., Feron, V.J. and van der Heijden, C.A. (1991) Chronic inhalation toxicity and carcinogenicity study of methyl bromide in wistar rats. *Fd Chem. Toxic.* Vol. 29, No. 1, pp. 31-39.

**EPL®****EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

Study Number B-91-8213/002

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.  
QUALITY ASSURANCE FINAL CERTIFICATION**

Chronic (29-Month) Inhalation Toxicity and Carcinogenicity  
Study Title: Study of Methyl Bromide in Rats: Reexamination of Nasal Cavity

Client Study: B-91-8213/002      EPL Project Coordinator: Dr. Hardisty

EPL Project Number: 303-009      EPL Pathologist: Dr. Hardisty

The following aspects of this study were inspected by the Quality Assurance Unit of Experimental Pathology Laboratories, Inc. Dates inspections were performed and findings reported to the Project Coordinator and Management are indicated below.

<u>Area Inspected</u>	<u>Dates</u>	
	<u>Inspection</u>	<u>Reporting</u>
EPL Project Sheets	June 6, 1997; July 15, 1997	June 6, 1997; July 15, 1997
Peer Review	June 23&25, 1997	June 25, 1997
Rough Draft Report	July 18, 1997	July 18, 1997
Final Report	July 21, 1997	July 21, 1997

Date of last quarterly facility inspection April, 1997

  
EPL Quality Assurance Unit7/21/97  
Date

Form No. 6-2 (12/01/96)

**EPL®**

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

**APPENDIX A**

**SLIDE REVIEW WORK SHEETS**

**52-WEEK INTERIM - MALES**

## SLIDE REVIEW WORK SHEET

Chemical Name <u>METHYL BROMIDE</u>				Chemical Number _____			
Laboratory <u>TNO</u>	Client Project Id. <u>B-91-8213/002</u>			Sacrifice _____	52-WEEK INTERIM		
Group Id <u>A</u>	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Dose <u>0 PPM</u>	Sex & Species <u>MALE RAT</u>	Action To Be Taken	
A010		4	NASAL CAVITY - NOT REMARKABLE	AGREE			
A020		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE			
A030		4	NASAL CAVITY - NOT REMARKABLE	AGREE			
A040		4	NASAL CAVITY - NOT REMARKABLE	AGREE			
A050		4	NASAL CAVITY - NOT REMARKABLE	AGREE			
A060		4	NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS, SLIGHT	AGREE			
A070		4	NASAL CAVITY - NOT REMARKABLE	AGREE			
A080		4	NASAL CAVITY - NOT REMARKABLE	AGREE			
A090		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (I-IV)			
A100		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (I-IV)			
			NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS, SLIGHT	AGREE			

**SLIDE REVIEW WORK SHEET**Chemical Name **METHYL BROMIDE**Laboratory **TNO**Client Project Id. **B-91-8213/002**

Chemical Number

Group Id **B**Sacrifice **52-WEEK INTERIM**Dose **3 PPM**Sex & Species **MALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
B010		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B020		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B030		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B040		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B050		2	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT (III)		
B060		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B070		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B080		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B090		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B100		2	NASAL CAVITY - NOT REMARKABLE	AGREE		

**SLIDE REVIEW WORK SHEET**Chemical Name **METHYL BROMIDE**

Chemical Number \_\_\_\_\_

Laboratory **TNO**Client Project Id. **B-91-8213/002**

Sacrifice \_\_\_\_\_

**52-WEEK INTERIM**Group Id **C**Dose **30 PPM**

Sex &amp; Species \_\_\_\_\_

**MALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C010		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C020		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C030		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C040		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C050		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C060		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C070		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C080		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C090		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C100		2	NASAL CAVITY - NOT REMARKABLE	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**Client Project Id. **B-91-8213/002****52-WEEK INTERIM**Group Id **D**Dose **90 PPM**

Sacrifice

**MALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D010		4	NASAL CAVITY - NOT REMARKABLE			
D020		4	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (III)		
D030		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
D040		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D050		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D060		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D070		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
D080		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D090		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT (III)		
				NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS	AGREE	
				NASAL CAVITY - HYPERKERATOSIS IN DUCTUS NASOLACHRYMALIS	AGREE	
D100		4	NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS, SEVERE	AGREE		

**EPL®**

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

**APPENDIX B**

**SLIDE REVIEW WORK SHEETS**

**52-WEEK INTERIM - FEMALES**

Chemical Name **METHYL BROMIDE****SLIDE REVIEW WORK SHEET**

Laboratory	TNO	Client Project Id.	B-91-8213/002	Sacrifice	52-WEEK INTERIM
Group Id	A	Dose	0 PPM	Sex & Species	FEMALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
A009		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
A019		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
A029		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
A039		4	NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS	AGREE		
A049		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
A059		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
A069		4	NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS, SLIGHT	AGREE		
A079		4	NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS, MODERATE	AGREE		
			NASAL CAVITY - HYPERKERATOSIS IN DUCTUS NASOLACHRYMALIS, SLIGHT	AGREE		
A089		4	NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS	AGREE		
A099		4	NASAL CAVITY - NOT REMARKABLE	AGREE		

Chemical Name METHYL BROMIDE**SLIDE REVIEW WORK SHEET**

Laboratory <u>TNO</u>				Client Project Id. <u>B-91-8213/002</u>				Chemical Number	
Group Id <u>B</u>		Dose <u>3 PPM</u>		Sex & Species <u>FEMALE RAT</u>		Sacrifice		52-WEEK INTERIM	
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments		Comments		Action To Be Taken	
B009		2	NASAL CAVITY - NOT REMARKABLE	AGREE					
B019		2	NASAL CAVITY - NOT REMARKABLE	AGREE					
B029		3	NASAL CAVITY - NOT REMARKABLE	AGREE					
B039		2	NASAL CAVITY - NOT REMARKABLE	AGREE					
B049		0	NASAL CAVITY - NO SECTION	AGREE					
B059		2	NASAL CAVITY - NOT REMARKABLE	AGREE					
B069		2	NASAL CAVITY - NOT REMARKABLE	AGREE					
B079		0	NASAL CAVITY - NO SECTION	AGREE					
B089		2	NASAL CAVITY - NOT REMARKABLE	AGREE					
B099		2	NASAL CAVITY - NOT REMARKABLE	AGREE					

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO** Client Project Id. **B-91-8213/002****52-WEEK INTERIM**Group Id **C** Dose **30 PPM** Sex & Species **FEMALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
						Sacrifice
C009		4	NASAL CAVITY - NOT REMARKABLE	AGREE		52-WEEK INTERIM
C019		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C029		1	NASAL CAVITY - NOT REMARKABLE	AGREE		
C039		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C049		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C059		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C069		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C079		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C089		2	NASAL CAVITY - BASAL-CELL HYPERPLASTA, VERY SLIGHT	AGREE		
C099		2	NASAL CAVITY - NOT REMARKABLE	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name METHYL BROMIDE

Chemical Number

Laboratory TNO

Client Project Id. B-91-8213/002

52-WEEK INTERIM

Group Id D

Dose 90 PPM

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D009		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
D019		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
D029		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
			NASAL CAVITY - PERIODONTITIS, SEVERE	AGREE		
D039		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
D049		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
D059		3	NASAL CAVITY - NOT REMARKABLE	AGREE		
D069		4	NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS	AGREE		
			NASAL CAVITY - PERIODONTITIS	AGREE		
			NASAL CAVITY - HYPERKERATOSIS OF SQUAMOUS EPITHELIUM	AGREE		
D079		4	NASAL CAVITY - NOT REMARKABLE	AGREE		
D089		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D099		4	NASAL CAVITY - AGGREGATES OF MC IN DUCTUS NASOLACHRYMALIS, SLIGHT	AGREE		
			NASAL CAVITY - HYPERKERATOSIS IN DUCTUS NASOLACHRYMALIS, SLIGHT	AGREE		

**EPL®**

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

**APPENDIX C**

**SLIDE REVIEW WORK SHEETS**

**104-WEEK INTERIM - MALES**

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**Client Project Id. **B-91-8213/002**Sacrifice **104-WEEK INTERIM**Group Id **A**Dose **0 PPM**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
A108		6	NASAL CAVITY - RHINITIS, MODERATE	AGREE		
			NASAL CAVITY - RESPIRATORY EPITHELIAL NEST-LIKE INFOLDS, MODERATE	AGREE		
A110		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A118		6	NASAL CAVITY - RHINITIS, SEVERE	AGREE		
			NASAL CAVITY - PERIODONTITIS, MODERATE	AGREE		
A120		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (I-VI)		
A128		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A138		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (III)		
A146		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A156		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A166		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NO REMARKABLE LESION - (I-VI)		
A176		6	NASAL CAVITY - RESPIRATORY EPITHELIAL NEST-LIKE INFOLDS, SLIGHT	AGREE		

Chemical Name **METHYL BROMIDE****SLIDE REVIEW WORK SHEET**

Laboratory <b>TNO</b>		Client Project Id. <b>B-91-8213/002</b>		Chemical Number	
Group Id	<b>B</b>	Dose	<b>3 PPM</b>	Sacrifice	<b>104-WEEK INTERIM</b>
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Action To Be Taken
B108		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B110		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B118		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B120		6	NASAL CAVITY - NO SECTION	NASAL CAVITY - NOT REMARKABLE (I-VI)	
B128		7	NASAL CAVITY - NO SECTION	NASAL CAVITY - ODONTOGENIC FIBROSARCOMA (I-VI)	
B138		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B146		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B156		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B166		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B176		2	NASAL CAVITY - NOT REMARKABLE	AGREE	

## SLIDE REVIEW WORK SHEET

Chemical Name METHYL BROMIDE

Chemical Number

Laboratory TNO Client Project Id. B-91-8213/002

104-WEEK INTERIM

Group Id C Dose 30 PPM

Sex &amp; Species MALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C108		2	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (III)		
C110		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C118		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C120		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C128		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C138		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C146		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C156		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C166		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C176		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name METHYL BROMIDELaboratory TNOClient Project Id. B-91-8213/002

Chemical Number

Group Id DSacrifice 104-WEEK INTERIMGroup Id DDose 90 PPMSex & Species MALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D108		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D110		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D118		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D120		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE		NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT (3)	
D128		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D138		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D146		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D156		6	NASAL CAVITY - MAXILLARY SINUS MONONUCLEAR-CELL INFILTRATE, MODERATE	AGREE		
D166		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D176		6	NASAL CAVITY - NOT REMARKABLE	AGREE		

**EPL®**

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

**APPENDIX D**

**SLIDE REVIEW WORK SHEETS**

**104-WEEK INTERIM - FEMALES**

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**Laboratory **TNO**Client Project Id. **B-91-8213/002**

Chemical Number

**104-WEEK INTERIM**Group Id **A**Dose **0 PPM**

Sacrifice

**FEMALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
A107		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A109		0	NASAL CAVITY - NO SECTION	AGREE		
A117		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A119		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (III)		
A127		6	NASAL CAVITY - TURBINATE MONONUCLEAR-CELL INFILTRATE, MODERATE	AGREE		
			NASAL CAVITY - NASOLACHRYMAL DUCT MONONUCLEAR-CELL INFILTRATE, MODERATE	AGREE		
A137		6	NASAL CAVITY - NASOLACHRYMAL DUCT MONONUCLEAR-CELL INFILTRATE, MODERATE	AGREE		
			NASAL CAVITY - BASAL-CELL INFILTRATE, MODERATE	AGREE		
A145		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT (III)		
			NASAL CAVITY - RHINITIS, MODERATE	AGREE		
A155		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (I-VI)		
A165		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (III)		
A175			NASAL CAVITY - MAXILLARY SINUS MONONUCLEAR-CELL INFILTRATE, MODERATE	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name	METHYL BROMIDE			Chemical Number			
Laboratory	TNO	Client Project Id. B-91-8213/002			Sacrifice	104-WEEK INTERIM	
Group Id	B	Dose 3 PPM			Sex & Species	FEMALE	RAT
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken	
B107		2	NASAL CAVITY - NOT REMARKABLE	AGREE			
B109		2	NASAL CAVITY - NOT REMARKABLE	AGREE			
B117		2	NASAL CAVITY - NOT REMARKABLE	AGREE			
B119		2	NASAL CAVITY - NOT REMARKABLE	AGREE			
B127		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE			
B137		2	NASAL CAVITY - NOT REMARKABLE	AGREE			
B145		2	NASAL CAVITY - NOT REMARKABLE	AGREE			
B155		2	NASAL CAVITY - NOT REMARKABLE	AGREE			
B165		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE			
B175		2	NASAL CAVITY - NOT REMARKABLE	AGREE			

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**Laboratory **TNO**Client Project Id. **B-91-8213/002**

Chemical Number

104-WEEK INTERIM

Group Id **C**Dose **30 PPM**

Sacrifice

**FEMALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C107		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C109		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C117		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (III)		
C119		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C127		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C137		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C145		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C155		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C165		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C175		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

Group Id **D**

Dose **90 PPM**

Chemical Number

Sacrifice

104-WEEK INTERIM

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D107		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D109		6	NASAL CAVITY - NASOLACHRYMAL DUCT MONONUCLEAR-CELL INFILTRATE, SLIGHT	AGREE		
D117		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
			NASAL CAVITY - NASOLACHRYMAL DUCT MONONUCLEAR-CELL INFILTRATE, MODERATE	AGREE		
D119		0	NASAL CAVITY - NO SECTION	AGREE		
D127		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D137		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
D145		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D155		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
			NASAL CAVITY - NASOLACHRYMAL DUCT MONONUCLEAR-CELL INFILTRATE, MODERATE	AGREE		
D165		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D175		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		

**EPL®**

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

**APPENDIX E**

**SLIDE REVIEW WORK SHEETS**

**TERMINAL - MALES**

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

TERMINAL

Group Id **A**

Dose **0 PPM**

MALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
A002		6	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (III)		
A004		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A006		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A012		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II) [INVOLVES SQUAMOUS EPITHELIUM OF NARES]		
A014		0	NASAL CAVITY - AUTOLYSIS	NASAL CAVITY - NO SLIDES PREPARED DUE TO AUTOLYSIS (-)		
A016		5	NASAL CAVITY - NOT REMARKABLE	AGREE		
A022		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A024		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A026		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A032		5	NASAL CAVITY - NOT REMARKABLE	AGREE		
A034		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II, III) [INVOLVES SQUAMOUS EPITHELIUM OF NARES AND TRANSITIONAL EPITHELIUM OF LATERAL WALL; NO OLFACTORY CHANGES]		
A036		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (II) [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]		
A042		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A044		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A046		6	NASAL CAVITY - NOT REMARKABLE	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name <b>METHYL BROMIDE</b>				Chemical Number	TERMINAL	
Laboratory	TNO	Client Project Id. <b>B-91-8213/002</b>		Sacrifice	Sex & Species	<b>MALE RAT</b>
Group Id	A	Dose <b>0 PPM</b>				
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
A052		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A054		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A056		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II) INVOLVES SQUAMOUS EPITHELIUM OF NARES; NO OLFACTORY CHANGES		
A062		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A064		0	NASAL CAVITY - NO SECTION	AGREE		
A066		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A072		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A074		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A076		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A082		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A084		6	NASAL CAVITY - METASTASIZING SQUAMOUS-CELL CARCINOMA	AGREE		
A086		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A092		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NO REMARKABLE LESION - (I-VI)		
A094		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
A096		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A102		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A104		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
A106		6	NASAL CAVITY - NOT REMARKABLE	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name METHYL BROMIDELaboratory TNOClient Project Id. B-91-8213/002

Chemical Number

Sacrifice

TERMINAL

Group Id ADose 0 PPM

Sex &amp; Species

MALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
A112		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A114		0	NASAL CAVITY - NO SECTION	AGREE		
A116		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A122		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A124		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A126		0	NASAL CAVITY - NO SECTION	AGREE		
A132		6	PSEUDOEPITHELIOMATOUS HYPERPLASTA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (I) [INVOLVES SQUAMOUS EPITHELIUM OF NARES]		
A134		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASTA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (II) [INVOLVES SQUAMOUS EPITHELIUM OF NARES; NO OLFACTORY CHANGES]		
A136		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
A142		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A144		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A152		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A154		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A162		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A164		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A172		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A174		6	NASAL CAVITY - NOT REMARKABLE	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name	METHYL BROMIDE			Chemical Number		
Laboratory	TNO	Client Project Id.		B-91-8213/002	Sacrifice	TERMINAL
Group Id	B	Dose	3 PPM		Sex & Species	MALE RAT
				Reviewing Pathologist's Comments		
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
B002		6	NASAL CAVITY - OSTEOSARCOMA	AGREE		
B004		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B006		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
B012		2	NASAL CAVITY - EPITHELIAL HYPERPLASIA, MODERATE	AGREE [INVOLVES SQUAMOUS EPITHELIUM OF NARES AND TRANSITIONAL EPITHELIUM OF LATERAL WALL; NO OLFACTORY CHANGES]		
B014		1	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - RHINITIS, MODERATE (ii,iii)		
B016		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (ii) [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]	NOT PRESENT IN SECTION - (ii,iii)	
B022		2	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT	NASAL CAVITY - RHINITIS, MODERATE (ii)	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]	
B024		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
B026		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B032		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B034		2	NASAL CAVITY - NOT REMARKABLE	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name	METHYL BROMIDE	Client Project Id. B-91-8213/002		Chemical Number
Laboratory	TNO	Dose 3 PPM		Sacrifice TERMINAL
Group Id	B	Sex & Species MALE RAT		
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments
B036		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE
B042		7	NASAL CAVITY - SQUAMOUS-CELL CARCINOMA	AGREE
B044		2	NASAL CAVITY - NOT REMARKABLE	AGREE
B046		2	NASAL CAVITY - NOT REMARKABLE	AGREE
B052		2	NASAL CAVITY - EPITHELIAL HYPERPLASIA, MODERATE	AGREE [INVOLVES RESPIRATORY AND TRANSITIONAL EPITHELIUM SECONDARY TO PERIODONTITIS; NO OLFACTORY CHANGES]
B054		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE
B056		2	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]
B062		2	NASAL CAVITY - NOT REMARKABLE	AGREE
B064		2	NASAL CAVITY - NOT REMARKABLE	AGREE
B066		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE
B072		4	NASAL CAVITY - NOT REMARKABLE	AGREE
B074		6	NASAL CAVITY - ODONTO-AMELOBLASTOMA	AGREE
B076		2	NASAL CAVITY - NOT REMARKABLE	AGREE
B082		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II, III)
B084		2	NASAL CAVITY - NOT REMARKABLE	AGREE

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

TERMINAL

Group Id **B**

Dose **3 PPM**

Sex & Species

MALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
B086		2	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II) [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]		
B092		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B094		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B096		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B102		2	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II, III) [INVOLVES RESPIRATORY AND TRANSITIONAL EPITHELIUM SECONDARY TO RHINITIS; NO OLFACTORY CHANGES]		
B104		1	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	NASAL CAVITY - RHINITIS, SLIGHT (II, III)	
B106		2	NASAL CAVITY - NOT REMARKABLE		INSUFFICIENT TISSUE - (III)	
B112		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B114		1	NASAL CAVITY - NOT REMARKABLE	AGREE		
B116		2	NASAL CAVITY - NOT REMARKABLE	AGREE	INSUFFICIENT TISSUE - (II, III)	
B122		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B124		5	NASAL CAVITY - SQUAMOUS-CELL CARCINOMA	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name METHYL BROMIDE

Laboratory TNO Client Project Id. B-91-8213/002

Chemical Number TERMINAL

Group Id B

Dose 3 PPM

Sacrifice

MALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
B126		1	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (III) [AUTOLYTIC CHANGE AND THICK SECTION]		
B132		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B134		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B136		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B142		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B144		0	NASAL CAVITY - NO SECTION	AGREE		
B152		0	NASAL CAVITY - NO SECTION	AGREE		
B154		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B162		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B164		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NO REMARKABLE LESION - (III)		
				NASAL CAVITY - INSUFFICIENT TISSUE (II)		
B172		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B174		2	NASAL CAVITY - NOT REMARKABLE	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

Sacrifice \_\_\_\_\_

**TERMINAL**

Group Id **C**

Dose **30 PPM**

Sex & Species \_\_\_\_\_

**MALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C002		0	NASAL CAVITY - NO SECTION	AGREE		
C004		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C006		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C012		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C014		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C016		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C022		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C024		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C026		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C032		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C034		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C036		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C042		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C044		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C046		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESSON - (II, III)		
C052		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C054		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
C056		2	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	NOT PRESENT IN SECTION - (II, III) [SAME CHANGE AS EPITHELIAL HYPERPLASIA]		

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

Chemical Number

**TERMINAL**

Group Id **C**

Dose **30 PPM**

Sacrifice

**MALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C062	Cont'd		NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT	AGREE [INVOLVES RESPIRATORY AND TRANSITIONAL EPITHELIUM SECONDARY RHINITIS; NO OLFACTORY CHANGES]		
C064		2	NASAL CAVITY - NOT REMARKABLE	AGREE	NASAL CAVITY - RHINITIS, SLIGHT (I,II)	
C066		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C066		2	NASAL CAVITY - NOT REMARKABLE	AGREE	NASAL CAVITY - INSUFFICIENT TISSUE (II)	
C072		8	NASAL CAVITY - FIBROSARCOMA	AGREE		
C074		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C076		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NOT PRESENT IN SECTION - (II,II)	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II) [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]	
C082		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE	NASAL CAVITY - RHINITIS, SLIGHT (II)	
C084		2	NASAL CAVITY - NOT REMARKABLE	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name	METHYL BROMIDE			Chemical Number
Laboratory	TNO	Client Project Id. B-91-8213/002		Sacrifice
Group Id	C	Dose	30 PPM	Sex & Species
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments
C086		2	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (II) [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]
C092			NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - RHINITIS, VERY SLIGHT (II)
C094		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE
C096		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C102		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C104		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE
C104		3	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (II) [INVOLVES RESPIRATORY AND TRANSITIONAL EPITHELIUM; NO OLFACTORY CHANGES / TWO SLIDES LABELED 11 (ONE IS NUMBERED 104C AND THE SECOND IS NUMBERED 104C ?); THE SECTIONS ARE FROM DIFFERENT BLOCKS]
C106		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C112		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE
C114		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C116		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C122		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE

**SLIDE REVIEW WORK SHEET**

Chemical Name	METHYL BROMIDE			Chemical Number
Laboratory	TNO	Client Project Id. B-91-8213/002		Sacrifice
Group Id	C	Dose	30 PPM	Sex & Species
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments
C124		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE
C126		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE
C132		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C134		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE
C136		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C142		2	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (II) [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]
C144		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NOT PRESENT IN SECTION - (II) [BOTH SLIDES LABELED AS LEVEL II BUT FROM DIFFERENT BLOCKS]
C152		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C154		2	NASAL CAVITY - NOT REMARKABLE	AGREE
C162		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE
C164		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE
C172		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE
C174		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE

## SLIDE REVIEW WORK SHEET

Chemical Name METHYL BROMIDELaboratory TNOClient Project Id. B-91-8213/002

TERMINAL

Group Id DDose 90 PPM

MALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D002		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT NASAL CAVITY - HYPERKERATOSIS, SLIGHT	AGREE		
D004		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D006		6	NASAL CAVITY - PSUEDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NOT PRESENT IN SECTION - (I-VI)		
			NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE		
D012		7	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D014		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D016		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
D022		6	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES SQUAMOUS RESPIRATORY AND TRANSITIONAL EPITHELIUM SECONDARY TO RHINITIS; NO OLFACTORY CHANGES]		
			NASAL CAVITY - RHINITIS, MODERATE (I-VI)			
D024		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D026		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D032		0	NASAL CAVITY - NO SECTION	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name <b>METHYL BROMIDE</b>				Chemical Number	
Laboratory	TNO	Client Project Id. <b>B-91-8213/002</b>		Sacrifice	TERMINAL
Group Id	D	Dose <b>90 PPM</b>		Sex & Species	MALE RAT
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	
D034		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D036		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D042		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE	
D044		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D046		5	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	
D052		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D054		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	
D056		6	NASAL CAVITY - HYPERKERATOSIS, VERY SLIGHT	AGREE	
D062		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D064		7	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (IV)	
D066		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D072		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D074		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE	
D076		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE	
			NASAL CAVITY - HYPERKERATOSIS, VERY SLIGHT	AGREE	
D082		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D084		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE	

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

TERMINAL

Group Id **D**

Dose **90 PPM**

MALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D086		7	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D092		5	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
D094		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D096		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D102		6	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (III)		
D104		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D106		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (II) [INVOLVES SQUAMOUS EPITHELIUM OF NARES AND TRANSITIONAL EPITHELIUM OF LATERAL WALL; NO OLFACTORY CHANGES]		
D112		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D114		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D116		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D122		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D124		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D126		5	NASAL CAVITY - NOT REMARKABLE	AGREE		
D132		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name	METHYL BROMIDE			Chemical Number		
Laboratory	TNO	Client Project Id.		B-91-8213/002	Sacrifice	TERMINAL
Group Id	D	Dose		90 PPM	Sex & Species	MALE RAT
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis		Reviewing Pathologist's Comments	
D134		7	NASAL CAVITY - NOT REMARKABLE		AGREE	
0136		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT		AGREE	
0142		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT		AGREE	
D144		0	NASAL CAVITY - NO SECTION		AGREE	
0152		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE		AGREE	
D154		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE		AGREE	
D162		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT		AGREE	
D164		5	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT		AGREE	
0172		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT		AGREE	
D174		6	NASAL CAVITY - NOT REMARKABLE		AGREE	

**EPL®**

**EXPERIMENTAL PATHOLOGY LABORATORIES, INC.**

**APPENDIX F**

**SLIDE REVIEW WORK SHEETS**

**TERMINAL - FEMALES**

**SLIDE REVIEW WORK SHEET**

Chemical Name	METHYL BROMIDE				Chemical Number
Laboratory	TNO	Client Project Id. B-91-8213/002			Sacrifice
Group Id	A	Dose	0 PPM	Sex & Species	FEMALE RAT
			Action To Be Taken		
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments
A001		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A003		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A005		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A011		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A013		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT ((1)) [INVOLVES RESPIRATORY EPITHELIUM OF NASAL SEPTUM]	
A015		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A021		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A023		12	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT	AGREE [INVOLVES RESPIRATORY AND TRANSITIONAL EPITHELIUM SECONDARY TO RHINITIS; NO OLFACTORY CHANGES]	
				NASAL CAVITY - RHINITIS, MODERATE (1-VI) [12 SLIDES (6 WITH RHINITIS; 6 WITHOUT RHINITIS); APPEAR TO BE FROM DIFFERENT ANIMALS]	
A025		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A031		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A033		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A035		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	
A041		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
A043		8	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT ((1))	
A045		6	NASAL CAVITY - NOT REMARKABLE	AGREE	

## SLIDE REVIEW WORK SHEET

Chemical Name		METHYL BROMIDE		Client Project Id.		B-91-8213/002		Chemical Number	
Laboratory	TNO			Dose		0 PPM		Sacrifice	
Group Id	A							Sex & Species	
Animal Id.	Histology Number	No. of Slides		Study Pathologist's Diagnosis		Reviewing Pathologist's Comments		Comments	
								Action To Be Taken	
A051		6		NASAL CAVITY - NOT REMARKABLE		AGREE			
A053		6		NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT		AGREE			
A055		6		NASAL CAVITY - NOT REMARKABLE		AGREE			
A061		6		NASAL CAVITY - NOT REMARKABLE		AGREE			
A063		6		NASAL CAVITY - NOT REMARKABLE		AGREE			
A065		6		NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT		NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (I) [INVOLVES SQUAMOUS EPITHELIUM OF NARES]			
A071		6		NASAL CAVITY - NOT REMARKABLE		NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II, III) [INVOLVES RESPIRATORY AND TRANSITIONAL EPITHELIUM SECONDARY TO RHINITIS AND PERIODONTITIS; NO OLFACTORY CHANGES]			
A073		6		NASAL CAVITY - NOT REMARKABLE		NASAL CAVITY - RHINITIS, MODERATE (II, III, IV)			
A075		7		NASAL CAVITY - NOT REMARKABLE		NASAL CAVITY - PERIODONTITIS, SLIGHT (III, IV)			
A081		6		NASAL CAVITY - NOT REMARKABLE		AGREE			
A083		6		NASAL CAVITY - NOT REMARKABLE		AGREE			
A085		7		NASAL CAVITY - NOT REMARKABLE		AGREE			
A091		6		NASAL CAVITY - RHINITIS, VERY SEVERE		AGREE			

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**

Chemical Number \_\_\_\_\_

Laboratory **TNO**Client Project Id. **B-91-8213/002**Group Id **A**Dose **0 PPM**

Sacrifice \_\_\_\_\_

Sex & Species **FEMALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
A093		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (I-VI)		
A095		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A101		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
A103		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A105		6	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT	AGREE [INVOLVES SQUAMOUS EPITHELIUM OF NARES AND TRANSITIONAL EPITHELIUM OF LATERAL WALL; NO OLFACTORY CHANGES]		
			NASAL CAVITY - HYPERKERATOSIS, SLIGHT	AGREE		
A111		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A113		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A115		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A121		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A123		6	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]		
A125		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A131		6	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES SQUAMOUS EPITHELIUM OF NARES; NO OLFACTORY CHANGES]		
A133		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A135		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A141		6	NASAL CAVITY - NOT REMARKABLE	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**

Laboratory	TNO	Client Project Id. <b>B-91-8213/002</b>		Sacrifice	Chemical Number
Group Id	A	Dose	0 PPM	Sex & Species	FEMALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
A143		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A151		5	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]		
A153		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A161		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A163		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A171		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES SQUAMOUS EPITHELIUM OF NARES]		
A173		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A129		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A139		6	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]		
A147		5	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
A149		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A157		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A159		0	NASAL CAVITY - NO SECTION	AGREE		
A167		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A169		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A177		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
A179		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name <b>METHYL BROMIDE</b>				Chemical Number	
Laboratory <b>TNO</b>		Client Project Id. <b>B-91-8213/002</b>		Sacrifice	TERMINAL
Group Id	<b>B</b>	Dose	<b>3 PPM</b>	Sex & Species	<b>FEMALE RAT</b>
				Action To Be Taken	
				Comments	
				Reviewing Pathologist's Comments	
				Study Pathologist's Diagnosis	
<b>Animal Id.</b>	<b>Histology Number</b>	<b>No. of Slides</b>			
B001		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	
B003		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B005		2	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT	AGREE [INVOLVES RESPIRATORY AND TRANSITIONAL EPITHELIUM SECONDARY; NO OLFACTORY CHANGES]	
B011		4	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE	
B013		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESSON - (II.III)	
B015		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B021		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESSON - (II.III)	
B023		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	
B025		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B031		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B033		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B035		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B041		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B043		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B045		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	
B051		2	NASAL CAVITY - NOT REMARKABLE	AGREE	
B053		2	NASAL CAVITY - NOT REMARKABLE	AGREE	

**SLIDE REVIEW WORK SHEET**

Chemical Name <b>METHYL BROMIDE</b>			Client Project Id. <b>B-91-8213/002</b>			Chemical Number
Laboratory	TNO	Group Id	B	Dose	3 PPM	Sacrifice
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
B055		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B061		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B063		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B065		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B071		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B073		2	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II) [INVOLVES SQUAMOUS EPITHELIUM OF MARES; NO OLFACTORY CHANGES]		
B075		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B081		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II, III)		
			NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]		
B083		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B085		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B091		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B093		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II, III)		
B095		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B101		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II, III)		
B103		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II, III)		

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**Client Project Id. **B-91-8213/002**

Sacrifice \_\_\_\_\_ TERMINAL

Group Id **B**Dose **3 PPM**Sex & Species **FEMALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
B105		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B111		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B113		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B115		2	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]		
B121		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B123		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B125		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B131		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B133		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B135		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B141		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B143		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B151		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B153		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B161		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II,III)		
B163		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B171		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II,III)		
B173		2	NASAL CAVITY - NOT REMARKABLE	INSUFFICIENT TISSUE - (II,III)		
B129		2	NASAL CAVITY - NOT REMARKABLE	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name METHYL BROMIDELaboratory TNOClient Project Id. B-91-8213/002

Chemical Number \_\_\_\_\_

Group Id B

Sacrifice \_\_\_\_\_ TERMINAL

Dose 3 PPMSex & Species FEMALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
						Dose 3 PPM
B139		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B147		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B149		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B157		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
B159		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B167		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B169		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
B177		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
B179		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
			NASAL CAVITY - RHINITIS, MODERATE (II, III)			

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

Chemical Number

**Group Id C**

Dose **30 PPM**

Sacrifice

**TERMINAL**

Sex & Species

**FEMALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C001		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C003		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C005		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C011		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C013		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C015		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C021		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C023		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C025		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C031		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C033		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C035		2	NASAL CAVITY - PSEUDOPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (III) [INVOLVES RESPIRATORY AND TRANSITIONAL EPITHELIUM SECONDARY TO RHINITIS; NO OLFACTORY CHANGES]		
C041		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C043		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C045		2	NASAL CAVITY - NOT REMARKABLE	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name METHYL BROMIDELaboratory TNOClient Project Id. B-91-8213/002

Chemical Number

Sacrifice \_\_\_\_\_

TERMINAL

Group Id CDose 30 PPM

Sex &amp; Species \_\_\_\_\_

FEMALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C051		3	NASAL CAVITY - NOT REMARKABLE			
C053		2	NASAL CAVITY - NOT REMARKABLE	AGREE [2 SLIDES LABELED III; ONE IS SEVERELY AUTOLYZED. NO AUTOLYSIS IN SECOND SECTION; APPEAR TO BE FROM DIFFERENT ANIMALS]		
C055		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C061		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C063		2	NASAL CAVITY - NOT REMARKABLE	NO REMARKABLE LESION - (II,III)		
C065		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C071		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C073		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C075		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C081		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C083		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C085		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C091		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C093		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C095		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

Sacrifice

**TERMINAL**

Group Id **C**

Dose **30 PPM**

Sex & Species

**FEMALE RAT**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C101		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C103		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
			NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL SECONDARY TO RHINITIS; NO OLFACTORY CHANGES]		
C105		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C111		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
C113		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C115		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C121		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C123		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (II, III)		
C125		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C131		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C133		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C135		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C141		2	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT (I)		

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**Client Project Id. **B-91-8213/002**

Sacrifice \_\_\_\_\_

Group Id **C**Dose **30 PPM**TERMINAL  
FEMALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
C143		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C151		1	NASAL CAVITY - NOT REMARKABLE	AGREE [ONLY LEVEL II IS PRESENT; TISSUE IS AUTOLYZED AND APPEARS SIMILAR TO AUTOLYZED SECTION III LABELED 51C]		
C153		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C161		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C163		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C171		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
C173		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II, III)		
C129		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C139		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C147		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C149		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C157		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C159		2	NASAL CAVITY - NOT REMARKABLE	AGREE		
C167		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
C169		0	NASAL CAVITY - NO SECTION	AGREE		
C177		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
C179		2	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	NO REMARKABLE LESION - (II, III)		

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Laboratory **TNO**

Client Project Id. **B-91-8213/002**

Chemical Number

Group Id **D**

Dose **90 PPM**

Sacrifice

TERMINAL

FEMALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D001		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D003		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D005		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D011		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
			NASAL CAVITY - EPITHELIAL HYPERPLASIA, MODERATE	AGREE [INVOLVES SQUAMOUS EPITHELIUM OF NARES; NO OLFACTORY CHANGES]		
D013		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D015		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D021		7	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D023		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D025		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D031		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
D033		5	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, SLIGHT	NOT PRESENT IN SECTION - (I-VI)		
			NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	NOT PRESENT IN SECTION - (I-VI)		
			NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT	AGREE [INVOLVES SQUAMOUS EPITHELIUM OF NARES; NO OLFACTORY CHANGES]		
			NASAL CAVITY - HYPERKERATOSIS, VERY SLIGHT	AGREE		

## SLIDE REVIEW WORK SHEET

Chemical Name **METHYL BROMIDE**Laboratory **TMO**Client Project Id. **B-91-8213/002**

Chemical Number \_\_\_\_\_

Sacrifice \_\_\_\_\_

TERMINAL

Group Id **D**Dose **90 PPM**

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D035		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
D041		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (I-VI)		
D043		5	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NO REMARKABLE LESION - (I-VI)		
D046		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D051		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
				NASAL CAVITY - RHINITIS, SEVERE (III,IV)		
D053		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE		
D055		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D061		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT (I-VI)		
D063		6	NASAL CAVITY - NOT REMARKABLE	NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT (II) INVOLVES SQUAMOUS EPITHELIUM OF NARES; NO OLFACTORY CHANGES]		
				NASAL CAVITY - RHINITIS, SLIGHT (II)		
D065		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D071		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D073		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D075		6	NASAL CAVITY - NOT REMARKABLE	AGREE		

## SLIDE REVIEW WORK SHEET

METHYL BROMIDE				Chemical Number	
Laboratory	TNO	Client Project Id. B-91-8213/002		Sacrifice	TERMINAL
Group Id	D	Dose 90 PPM		Sex & Species	FEMALE RAT
Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments
D081		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	NO REMARKABLE LESION - (I-VI)	Action To Be Taken
D083		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE [AUTOLYSIS PRESENT]	
D085		6	NASAL CAVITY - EPITHELIAL HYPERPLASIA, MODERATE	AGREE [INVOLVES TRANSITIONAL EPITHELIUM ON LATERAL WALL; NO OLFACTORY CHANGES]	
D091		6	NASAL CAVITY - NOT REMARKABLE	AGREE	
D093		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE	
D095		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	
D101		0	NASAL CAVITY - NO SECTION	AGREE	
D103		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE	
D105		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, VERY SLIGHT	AGREE	
D111		6	NASAL CAVITY - HYPERKERATOSIS, VERY SLIGHT	AGREE	
D113		9	NASAL CAVITY - NOT REMARKABLE	AGREE	
D115		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE	
D121		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE	

**SLIDE REVIEW WORK SHEET**

Chemical Name **METHYL BROMIDE**

Chemical Number

Laboratory **TNO**

Sacrifice

Client Project Id. **B-91-8213/002**

TERMINAL

Group Id **D**

Sex & Species

Dose **90 PPM**

FEMALE RAT

Animal Id.	Histology Number	No. of Slides	Study Pathologist's Diagnosis	Reviewing Pathologist's Comments	Comments	Action To Be Taken
D123		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT NASAL CAVITY - EPITHELIAL HYPERPLASIA, SLIGHT	NOT PRESENT IN SECTION - (I-VI)		
D125		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D131		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, MODERATE	AGREE		
D133		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D135		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		
D141		6	NASAL CAVITY - EPITHELIAL HYPERPLASIA, VERY SLIGHT	AGREE [INVOLVES SQUAMOUS EPITHELIUM OF NARES; NO OLFACTORY CHANGES]	NOT PRESENT IN SECTION - (I-VI)	
D143		6	NASAL CAVITY - PSEUDOEPITHELIOMATOUS HYPERPLASIA, VERY SLIGHT	AGREE		
D151		6	NASAL CAVITY - NOT REMARKABLE	AGREE		
D153		6	NASAL CAVITY - BASAL-CELL HYPERPLASIA, SLIGHT	AGREE		

## TRIAGE of 8(e) Submissions

Date sent to triage: \_\_\_\_\_

NON-CAP

CAP

Submission number: 14.001 A

TSCA Inventory: Y N D

---

### **STUDY TYPE (circle appropriate):**

**Cheng-Chun Lee (E609C)**

ATOX      SBTOX      SEN      w/NEUR

**Larry Newsome (E425)**

ECO      AQUATO

**Katherine Anitole (E611G)**

RTOX/DTOX

**Daljit Sawhney (E611A)**

GTOX      STOX

**Deborah Norris (E602)**

NEUR

**Jeff Beaubier (E608)**

EPI

**Ron Ward (E611F)**

IMMUNO/ALLERG

**David Lai (E611B)**

CARC

**Michael Cimino (E611D)**

GTOX

**Leonard Keifer (E611C)**

META/PHARM

### **NOTES:**

**CECAT/STRIAGE TRACKING DATABASE ENTRY FORM**

CECAT DATA:  
Submission # 8EHO-0877-4001 SEQ A

TYPE INT SUPP FLWP

SUBMITTER NAME: F&H

Chemical Manufacturers Assoc.

SUB DATE: 08-15-97 OTS DATE: 08-19-97

CHEMICAL NAME

methyl bromide

INFORMATION REQUESTED FLWP DATE	
0501	NO INFO REQUESTED
0502	INFO REQUESTED (TECH)
0503	INFO REQUESTED (VOL ACTIONS)
0504	INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION

- 0639 REFER TO CHEMICAL SCREENING
- 0678 CAP NOTICE

CAS #

74-83-9

VOLUNTARY ACTIONS

- 0401 NO ACTION REPORTED
- 0402 STUDIES PLANNED/UNDERWAY
- 0403 NOTIFICATION OF WORKER/OTHERS
- 0404 LABEL/MSDS CHANGES
- 0406 PROCESS/HANDLING CHANGES
- 0407 PRODUCTION DISCONTINUED
- 0408 CONFIDENTIAL

INFORMATION TYPE:

P F C	INFORMATION TYPE:	P F C	INFORMATION TYPE:
020	ONCO (HUMAN)	01 02 04	0216 EPI/CLIN
020	ONCO (ANIMAL)	01 02 04	0217 HUMAN EXPOS (PROD CONTAM)
0203	CELL TRANS (IN VITRO)	01 02 04	0218 HUMAN EXPOS (ACCIDENTAL)
0204	MUTA (IN VITRO)	01 02 04	0219 HUMAN EXPOS (MONITORING)
0205	MUTA (IN VIVO)	01 02 04	0220 ECO/AQUA TOX.
0206	REPRO/TERATO (HUMAN)	01 02 04	0221 ENV. OCCREL/FATE
0207	REPRO/TERATO (ANIMAL)	01 02 04	0222 EMER. INCL. OF ENV. CONTAM.
0208	NEURO (HUMAN)	01 02 04	0223 RESPONSE REQUEST DELAY
0209	NEURO (ANIMAL)	01 02 04	0224 PROD/COMP/CHEM ID
0210	ACUTE TOX. (HUMAN)	01 02 04	0225 REPORTING RATIONALE
0211	CHR. TOX. (HUMAN)	01 02 04	0226 CONFIDENTIAL
0212	ACUTE TOX. (ANIMAL)	01 02 04	0227 ALLERG (HUMAN)
0213	SUBACUTE TOX. (ANIMAL)	01 02 04	0228 ALLERG (ANIMAL)
0214	SUB CHRONIC TOX. (ANIMAL)	01 02 04	0239 METAB/PHARMAO (ANIMAL)
0215	CHRONIC TOX. (ANIMAL)	01 02 04	0240 METAB/PHARMAO (ANIMAL)

TRIAGE DATA: NON-CBI INVENTORY:

ONGOING REVIEW:

YES (DROP/REFER)

NO (CONTINUE)

DETERMINE

COMMENTS:

TOXICOLOGICAL CONCERN:

USE:

LOW

MEDIUM

HIGH

PRODUCTION:

"14001A" = "H" = "WISTAR RATS (50-60/SEX/CONCENTRATION) WERE EXPOSED VIA INHALATION TO 0, 3, 30, OR 90 PPM METHYL BROMIDE (CAS NO.- 000074-83-9) FOR 6 HOURS/DAY, 5 DAYS/WEEK, FOR 29 MONTHS. 10 RATS/SEX/DOSE WERE KILLED AT 52 AND 104 WEEKS. STATISTICALLY SIGNIFICANT INCREASES IN BASAL CELL HYPERPLASIA OF OLFACTORY EPITHELIUM IN THE NASAL CAVITY OCCURRED IN RATS EXPOSED TO 30 AND 90 PPM. THE NOEL WAS 3 PPM."